The World Health Organization (WHO) invites vendors to submit an Expression of Interest (EOI) for a WHO EVALUATION OF LATERAL FLOW IMMUNOASSAYS FOR THE DETECTION OF RUBELLA IgM FOR SURVEILLANCE which address the following objectives: Ensure continued availability of Rubella in vitro diagnostics that enable early outbreak detection and assessment of Rubella risks. Improve access to accurate, reliable Rubella LFTs in high‑risk countries to support timely outbreak response and vaccination planning. Assess whether commercial products meet WHO standards for safety, quality, and performance for use in Rubella surveillance. Include eligible LFTs that are single‑use, instrument‑free test kits containing all required materials (specimen collection, reagents, consumables) and meeting the specifications in the WHO target product profile (TPP). Optional readers may be included. For details please refer to Annex - REOI Details and respond no later than the closing date at the email :[email protected]. NOTE: ALL EMAIL CORRESPONDANCE MUST BEAR THE EOI REFERENCE NUMBER 2026-EOI-BP-23_ Rubella